MyoKardia Stock Price, News & Analysis (NASDAQ:MYOK)

$35.25 -0.45 (-1.26 %)
(As of 11/24/2017 06:17 AM ET)
Previous Close$35.25
Today's Range$34.50 - $35.85
52-Week Range$10.55 - $49.55
Volume231,391 shs
Average Volume292,723 shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.58

About MyoKardia (NASDAQ:MYOK)

MyoKardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio7.07%
Quick Ratio7.07%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.20 million
Price / Sales32.14
Cash FlowN/A
Price / CashN/A
Book Value$6.90 per share
Price / Book5.11

Profitability

Trailing EPS($0.76)
Net Income$-13,150,000.00
Net Margins-53.49%
Return on Equity-14.92%
Return on Assets-11.53%

Miscellaneous

Employees78
Outstanding Shares35,740,000

Frequently Asked Questions for MyoKardia (NASDAQ:MYOK)

What is MyoKardia's stock symbol?

MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."

How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) posted its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.42) EPS for the quarter, hitting analysts' consensus estimates of ($0.42). The biotechnology company had revenue of $5.63 million for the quarter, compared to analysts' expectations of $6.10 million. MyoKardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. MyoKardia's revenue was up 58.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.35) EPS. View MyoKardia's Earnings History.

Where is MyoKardia's stock going? Where will MyoKardia's stock price be in 2017?

5 analysts have issued 1 year target prices for MyoKardia's shares. Their predictions range from $48.00 to $65.00. On average, they anticipate MyoKardia's share price to reach $55.00 in the next twelve months. View Analyst Ratings for MyoKardia.

Who are some of MyoKardia's key competitors?

Who are MyoKardia's key executives?

MyoKardia's management team includes the folowing people:

  • Tassos Anastasios Gianakakos, President, Chief Executive Officer, Director (Age 44)
  • June Lee M.D., Chief Operating Officer (Age 51)
  • Jake Bauer, Senior Vice President - Finance and Corporate Development (Age 38)
  • Joseph Lambing Ph.D., Senior Vice President - Nonclinical and Pharmaceutical Development (Age 54)
  • Robert Scott McDowell Ph.D., Senior Vice President - Drug Discovery (Age 59)
  • Marc Semigran M.D., Chief Medical Officer (Age 60)
  • Mark L. Perry J.D., Interim Non-Executive Chairman of the Board, Lead Independent Director (Age 61)
  • Kevin P. Starr, Director (Age 54)
  • Sunil Agarwal M.D., Independent Director (Age 47)
  • Mary B. Cranston, Independent Director (Age 69)

Who owns MyoKardia stock?

MyoKardia's stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (1.54%), Wells Fargo & Company MN (1.17%), VHCP Management II LLC (0.74%), RTW Investments LP (0.71%), Fernwood Investment Management LLC (0.69%) and JPMorgan Chase & Co. (0.46%). Company insiders that own MyoKardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for MyoKardia.

Who sold MyoKardia stock? Who is selling MyoKardia stock?

MyoKardia's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OxFORD Asset Management LLP, Essex Investment Management Co. LLC, Dynamic Technology Lab Private Ltd, Fiduciary Trust Co. and Perceptive Advisors LLC. Company insiders that have sold MyoKardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr and Rock Ventures Ii LP Third. View Insider Buying and Selling for MyoKardia.

Who bought MyoKardia stock? Who is buying MyoKardia stock?

MyoKardia's stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, VHCP Management II LLC, RTW Investments LP, Fernwood Investment Management LLC, Candriam Luxembourg S.C.A., EAM Investors LLC, Jasper Ridge Partners L.P. and Nationwide Fund Advisors. Company insiders that have bought MyoKardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for MyoKardia.

How do I buy MyoKardia stock?

Shares of MyoKardia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MyoKardia's stock price today?

One share of MyoKardia stock can currently be purchased for approximately $35.25.

How big of a company is MyoKardia?

MyoKardia has a market capitalization of $1.28 billion and generates $39.20 million in revenue each year. The biotechnology company earns $-13,150,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. MyoKardia employs 78 workers across the globe.

How can I contact MyoKardia?

MyoKardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for MyoKardia (MYOK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about MyoKardia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for MyoKardia (NASDAQ:MYOK)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.883.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $55.00$55.00$42.60$26.00
Price Target Upside: 35.14% upside44.74% upside5.51% upside94.03% upside

Consensus Price Target History for MyoKardia (NASDAQ:MYOK)

Price Target History for MyoKardia (NASDAQ:MYOK)

Analysts' Ratings History for MyoKardia (NASDAQ:MYOK)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017WedbushReiterated RatingOutperform$51.00HighView Rating Details
9/19/2017Credit Suisse GroupReiterated RatingOutperform -> Outperform$45.00 -> $55.00HighView Rating Details
8/21/2017BMO Capital MarketsReiterated RatingOutperform$45.00 -> $65.00HighView Rating Details
8/7/2017Cowen IncBoost Price TargetOutperform$28.00 -> $56.00HighView Rating Details
8/7/2017Wells Fargo & CompanyReiterated RatingOutperform$31.00 -> $48.00HighView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for MyoKardia (NASDAQ:MYOK)

Earnings by Quarter for MyoKardia (NASDAQ:MYOK)

Earnings History by Quarter for MyoKardia (NASDAQ MYOK)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.42)($0.42)$6.10 million$5.63 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.41)$6.73 million$5.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MyoKardia (NASDAQ:MYOK)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.39)($0.39)($0.39)
Q4 20171($0.40)($0.40)($0.40)
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MyoKardia (NASDAQ:MYOK)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MyoKardia (NASDAQ MYOK)

Insider Ownership Percentage: 33.40%
Institutional Ownership Percentage: 44.93%
Insider Trades by Quarter for MyoKardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Insider Trades by Quarter for MyoKardia (NASDAQ MYOK)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2017Anastasios GianakakosCEOSell4,300$40.23$172,989.00View SEC Filing  
10/4/2017Anastasios GianakakosInsiderSell4,300$40.86$175,698.00View SEC Filing  
10/3/2017Kevin P StarrDirectorSell75,313$40.28$3,033,607.64View SEC Filing  
9/26/2017Kevin P StarrDirectorSell601,400$43.00$25,860,200.00View SEC Filing  
9/26/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell400,000$43.00$17,200,000.00View SEC Filing  
9/25/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell201,400$43.00$8,660,200.00View SEC Filing  
9/11/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell221,250$41.30$9,137,625.00View SEC Filing  
9/8/2017Kevin P StarrDirectorSell201,250$41.01$8,253,262.50View SEC Filing  
9/5/2017Anastasios GianakakosInsiderSell4,300$43.02$184,986.00View SEC Filing  
8/22/2017Joseph LambingInsiderSell5,000$45.00$225,000.00View SEC Filing  
8/15/2017Joseph LambingInsiderSell5,000$40.00$200,000.00View SEC Filing  
8/14/2017SanofiMajor ShareholderBuy350,000$35.50$12,425,000.00View SEC Filing  
8/14/2017Wendy L YarnoDirectorBuy1,408$35.50$49,984.00View SEC Filing  
8/8/2017Joseph LambingInsiderSell15,000$30.00$450,000.00View SEC Filing  
8/7/2017Jake BauerInsiderSell15,000$28.33$424,950.00View SEC Filing  
8/4/2017Anastasios GianakakosCEOSell4,300$16.62$71,466.00View SEC Filing  
7/25/2017Anastasios GianakakosInsiderSell32,988$15.00$494,820.00View SEC Filing  
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.00View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MyoKardia (NASDAQ MYOK)

Source:
DateHeadline
MyoKardia, Inc. (MYOK) Given Consensus Rating of "Buy" by BrokeragesMyoKardia, Inc. (MYOK) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 20 at 5:44 PM
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular CompliancePreclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
finance.yahoo.com - November 18 at 6:22 AM
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable BiosensorMyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
finance.yahoo.com - November 14 at 3:20 AM
Myokardia Inc (MYOK) Q3:17 Update At First GlanceMyokardia Inc (MYOK) Q3:17 Update At First Glance
finance.yahoo.com - November 9 at 6:46 AM
MyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : November 8, 2017MyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : November 8, 2017
finance.yahoo.com - November 9 at 6:46 AM
MyoKardia, Inc. (MYOK) CEO Anastasios Gianakakos Sells 4,300 SharesMyoKardia, Inc. (MYOK) CEO Anastasios Gianakakos Sells 4,300 Shares
www.americanbankingnews.com - November 8 at 7:38 PM
TheStreet Downgrades MyoKardia, Inc. (MYOK) to D+TheStreet Downgrades MyoKardia, Inc. (MYOK) to D+
www.americanbankingnews.com - November 7 at 9:36 AM
MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017
finance.yahoo.com - November 7 at 7:14 AM
Reviewing Viking Therapeutics (VKTX) & MyoKardia (MYOK)Reviewing Viking Therapeutics (VKTX) & MyoKardia (MYOK)
www.americanbankingnews.com - November 7 at 3:28 AM
Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 6 at 3:48 AM
MyoKardia Reports Third Quarter 2017 Financial Results and Operational ProgressMyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress
finance.yahoo.com - November 4 at 6:53 AM
MyoKardia, Inc. (MYOK) Posts Quarterly  Earnings Results, Meets EstimatesMyoKardia, Inc. (MYOK) Posts Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - November 3 at 11:58 PM
MyoKardia Announces Presentations at 2017 American Heart Association Scientific SessionsMyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions
finance.yahoo.com - November 2 at 6:40 AM
MyoKardia, Inc. (MYOK) to Release Quarterly Earnings on MondayMyoKardia, Inc. (MYOK) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 10:22 AM
MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017
finance.yahoo.com - October 27 at 8:16 AM
MyoKardia, Inc. (MYOK) Given Consensus Recommendation of "Buy" by BrokeragesMyoKardia, Inc. (MYOK) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 26 at 9:38 PM
Relative Strength Alert For MyoKardiaRelative Strength Alert For MyoKardia
www.nasdaq.com - October 19 at 6:37 AM
MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017
finance.yahoo.com - October 13 at 7:10 AM
MyoKardia, Inc. (MYOK) Lowered to Sell at Zacks Investment ResearchMyoKardia, Inc. (MYOK) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - October 11 at 6:32 AM
ETFs with exposure to MyoKardia, Inc. : October 10, 2017ETFs with exposure to MyoKardia, Inc. : October 10, 2017
finance.yahoo.com - October 11 at 1:30 AM
MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 9 at 3:33 PM
Myokardia Inc (MYOK) Insider Anastasios Gianakakos Sells 4,300 SharesMyokardia Inc (MYOK) Insider Anastasios Gianakakos Sells 4,300 Shares
www.americanbankingnews.com - October 6 at 7:48 PM
Kevin P. Starr Sells 75,313 Shares of MyoKardia, Inc. (MYOK) StockKevin P. Starr Sells 75,313 Shares of MyoKardia, Inc. (MYOK) Stock
www.americanbankingnews.com - October 4 at 4:36 PM
MyoKardia, Inc. (MYOK) Receives Average Recommendation of "Buy" from BrokeragesMyoKardia, Inc. (MYOK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 7:16 PM
MyoKardia Provides Update on MYK-491 Clinical Progress - GlobeNewswire (press release)MyoKardia Provides Update on MYK-491 Clinical Progress - GlobeNewswire (press release)
www.globenewswire.com - September 29 at 6:19 PM
MyoKardia Provides Update on MYK-491 Clinical ProgressMyoKardia Provides Update on MYK-491 Clinical Progress
www.nasdaq.com - September 28 at 12:48 PM
BRIEF-MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-endBRIEF-MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-end
www.reuters.com - September 28 at 12:48 PM
MyoKardia, Inc. (MYOK) Major Shareholder Sells $8,660,200.00 in StockMyoKardia, Inc. (MYOK) Major Shareholder Sells $8,660,200.00 in Stock
www.americanbankingnews.com - September 27 at 7:26 PM
MyoKardia, Inc. (MYOK) Major Shareholder Sells $17,200,000.00 in StockMyoKardia, Inc. (MYOK) Major Shareholder Sells $17,200,000.00 in Stock
www.americanbankingnews.com - September 27 at 7:26 PM
MyoKardia, Inc. (MYOK) Director Kevin P. Starr Sells 601,400 SharesMyoKardia, Inc. (MYOK) Director Kevin P. Starr Sells 601,400 Shares
www.americanbankingnews.com - September 27 at 4:28 PM
MyoKardia, Inc. (MYOK) Receives Outperform Rating from WedbushMyoKardia, Inc. (MYOK) Receives Outperform Rating from Wedbush
www.americanbankingnews.com - September 20 at 11:50 AM
MyoKardias (MYOK) Outperform Rating Reaffirmed at Credit Suisse GroupMyoKardia's (MYOK) Outperform Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - September 19 at 8:58 AM
MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (FormerlyMyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly
www.nasdaq.com - September 19 at 12:55 AM
MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific MeetingMyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
finance.yahoo.com - September 19 at 12:55 AM
MyoKardia Unveils More Phase 2 Data on Heart Disease TreatmentMyoKardia Unveils More Phase 2 Data on Heart Disease Treatment
finance.yahoo.com - September 19 at 12:55 AM
Contrasting MyoKardia (MYOK) and Ocata Therapeutics (OCAT)Contrasting MyoKardia (MYOK) and Ocata Therapeutics (OCAT)
www.americanbankingnews.com - September 17 at 12:54 PM
Kevin P. Starr Sells 201,250 Shares of MyoKardia, Inc. (MYOK) StockKevin P. Starr Sells 201,250 Shares of MyoKardia, Inc. (MYOK) Stock
www.americanbankingnews.com - September 12 at 7:34 PM
Rock Ventures Ii L.P. Third Sells 221,250 Shares of MyoKardia, Inc. (MYOK) StockRock Ventures Ii L.P. Third Sells 221,250 Shares of MyoKardia, Inc. (MYOK) Stock
www.americanbankingnews.com - September 12 at 7:34 PM
Anastasios Gianakakos Sells 4,300 Shares of MyoKardia, Inc. (MYOK) StockAnastasios Gianakakos Sells 4,300 Shares of MyoKardia, Inc. (MYOK) Stock
www.americanbankingnews.com - September 7 at 8:08 PM
Head-To-Head Review: Cerulean Pharma (DARE) versus MyoKardia (MYOK)Head-To-Head Review: Cerulean Pharma (DARE) versus MyoKardia (MYOK)
www.americanbankingnews.com - September 7 at 10:03 AM
MyoKardia to Present at Two Upcoming Investor Conferences in SeptemberMyoKardia to Present at Two Upcoming Investor Conferences in September
finance.yahoo.com - August 31 at 7:34 AM
Short Interest in MyoKardia, Inc. (MYOK) Increases By 61.0%Short Interest in MyoKardia, Inc. (MYOK) Increases By 61.0%
www.americanbankingnews.com - August 28 at 1:48 AM
Insider Selling: MyoKardia, Inc. (MYOK) Insider Sells 5,000 Shares of StockInsider Selling: MyoKardia, Inc. (MYOK) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - August 24 at 7:34 PM
MyoKardia, Inc. (MYOK) Rating Reiterated by BMO Capital MarketsMyoKardia, Inc. (MYOK) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - August 21 at 10:40 AM
MyoKardia (MYOK) Looks Good: Stock Adds 6.32% in SessionMyoKardia (MYOK) Looks Good: Stock Adds 6.32% in Session
finance.yahoo.com - August 17 at 5:39 AM
MyoKardia, Inc. (MYOK) Director Wendy L. Yarno Acquires 1,408 SharesMyoKardia, Inc. (MYOK) Director Wendy L. Yarno Acquires 1,408 Shares
www.americanbankingnews.com - August 16 at 9:34 PM
MyoKardia, Inc. (MYOK) Insider Sells $200,000.00 in StockMyoKardia, Inc. (MYOK) Insider Sells $200,000.00 in Stock
www.americanbankingnews.com - August 16 at 8:46 PM
MyoKardia, Inc. (MYOK) Major Shareholder Sanofi Acquires 350,000 SharesMyoKardia, Inc. (MYOK) Major Shareholder Sanofi Acquires 350,000 Shares
www.americanbankingnews.com - August 16 at 1:40 PM
Wedbush Weighs in on MyoKardia, Inc.s Q3 2017 Earnings (NASDAQ:MYOK)Wedbush Weighs in on MyoKardia, Inc.'s Q3 2017 Earnings (NASDAQ:MYOK)
www.americanbankingnews.com - August 14 at 2:30 AM
MyoKardia, Inc. (MYOK) Receives Average Recommendation of "Buy" from AnalystsMyoKardia, Inc. (MYOK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 6:38 PM

Social Media

Financials

Chart

MyoKardia (NASDAQ MYOK) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.